TP53 and neoplasm: Many in vivo studies have documented tumor regression in response to wild-type p53 restoration either through genetic means, i.e., in inducible transgenic models [16,17], gene therapy [18,19] or by use of p53 pathway-restoring therapeutic agents [20,21].